Kinnate Biopharma : Results of Operations and Financial Condition - Form 8-K
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a... | April 17, 2023
Source: marketscreener.com
Page 3 - Single Agent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Single Agent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Single Agent Today - Breaking & Trending Today
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
Results from Phase 3 KEYNOTE-966 to be presented at AACR 2023 Annual Meeting during Clinical Trials Plenary Session, included in official meeting press program and published simultaneously in The... | April 16, 2023
Source: marketscreener.com
Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma
Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.
Source: onclive.com
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coform
Blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel aloneRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe...
Source: pharmiweb.com
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers,...
Source: prnewswire.com